Published in J Bone Miner Res on July 01, 2003
The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov (2009) 6.23
Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol (2004) 3.23
Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A (2011) 2.24
Endocrine functions of bone in mineral metabolism regulation. J Clin Invest (2008) 2.19
Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab (2009) 2.12
Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev (2012) 1.97
Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int (2012) 1.82
Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol (2013) 1.78
FGF-23: More than a regulator of renal phosphate handling? J Bone Miner Res (2010) 1.63
Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol (2009) 1.58
Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone (2004) 1.57
Assessment of 24,25(OH)2D levels does not support FGF23-mediated catabolism of vitamin D metabolites. Kidney Int (2012) 1.57
Vitamin D: metabolism. Endocrinol Metab Clin North Am (2010) 1.56
Pathogenic role of Fgf23 in Dmp1-null mice. Am J Physiol Endocrinol Metab (2008) 1.55
Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp Cell Res (2012) 1.41
Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol (2012) 1.37
Comparison of two assays for fibroblast growth factor (FGF)-23. J Bone Miner Metab (2005) 1.36
Evidence for a bone-kidney axis regulating phosphate homeostasis. J Clin Invest (2003) 1.33
Regulation of phosphate transport in proximal tubules. Pflugers Arch (2008) 1.33
Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab (2007) 1.31
Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol (2005) 1.30
Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol (2008) 1.30
The wrickkened pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med (2004) 1.28
FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol (2008) 1.28
Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. Physiol Rev (2016) 1.25
Fibroblast growth factor 23: state of the field and future directions. Trends Endocrinol Metab (2012) 1.21
A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One (2012) 1.20
Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol (2007) 1.18
Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin. Bone (2006) 1.18
Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatr Nephrol (2009) 1.14
Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation. J Endocrinol (2010) 1.13
Secreted klotho and chronic kidney disease. Adv Exp Med Biol (2012) 1.13
FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med (2014) 1.09
Calcium regulates FGF-23 expression in bone. Endocrinology (2013) 1.09
C-terminal FGF23 fragments: present but not seen? Osteoporos Int (2013) 1.08
Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization. Calcif Tissue Int (2011) 1.07
Recent advances in renal phosphate handling. Nat Rev Nephrol (2010) 1.04
Racial differences in markers of mineral metabolism in advanced chronic kidney disease. Clin J Am Soc Nephrol (2012) 1.03
The role of FGF23 in CKD--with or without Klotho. Nat Rev Nephrol (2012) 1.02
Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO. J Biol Chem (2009) 0.98
The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature. Semin Nephrol (2009) 0.96
Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism. Int J Pediatr Endocrinol (2009) 0.93
What's new in hypophosphataemic rickets? Eur J Pediatr (2008) 0.92
Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice. Endocrinology (2012) 0.90
Relationship of associated secondary hyperparathyroidism to serum fibroblast growth factor-23 in end stage renal disease: a case-control study. Indian J Endocrinol Metab (2011) 0.89
Fibroblast growth factor-23: what we know, what we don't know, and what we need to know. Nephrol Dial Transplant (2013) 0.89
Using (18)F-FDG PET/CT to Detect an Occult Mesenchymal Tumor Causing Oncogenic Osteomalacia. Nucl Med Mol Imaging (2011) 0.88
Biomarkers of kidney injury and klotho in patients with atherosclerotic renovascular disease. Clin J Am Soc Nephrol (2014) 0.87
Novel bone endocrine networks integrating mineral and energy metabolism. Curr Osteoporos Rep (2013) 0.86
Association of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: the Osteoporotic Fractures in Men (MrOS) study. J Bone Miner Res (2013) 0.86
Role of prostaglandins in the pathogenesis of X-linked hypophosphatemia. Pediatr Nephrol (2006) 0.85
Fibroblast growth factor-23 increases mouse PGE2 production in vivo and in vitro. Am J Physiol Renal Physiol (2005) 0.83
Short daily hemodialysis is associated with lower plasma FGF23 levels when compared with conventional hemodialysis. Nephrol Dial Transplant (2013) 0.83
Glucocorticoids and osteocyte autophagy. Bone (2013) 0.82
Phosphatonin washout in Hyp mice proximal tubules: evidence for posttranscriptional regulation. Am J Physiol Renal Physiol (2004) 0.82
Fibroblast growth factor 23 and 25-hydroxyvitamin D levels are associated with estimated glomerular filtration rate decline. Kidney Int Suppl (2011) (2013) 0.82
Interactions of vitamin D and the proximal tubule. Pediatr Nephrol (2015) 0.82
Fibroblast growth factor 23 and bone mineralisation. Int J Oral Sci (2015) 0.81
Plasma FGF23 levels and heart rate variability in patients with stage 5 CKD. Osteoporos Int (2014) 0.80
Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients. PLoS One (2012) 0.80
Three novel mutations in the PHEX gene in Chinese subjects with hypophosphatemic rickets extends genotypic variability. Calcif Tissue Int (2011) 0.80
Clinical practice. Fibroblast growth factor (FGF)23: a new hormone. Eur J Pediatr (2010) 0.80
FGF23: its role in renal bone disease. Pediatr Nephrol (2006) 0.79
FGF23 analysis of a Chinese family with autosomal dominant hypophosphatemic rickets. J Bone Miner Metab (2011) 0.79
Clinical features of CKD-MBD in Japan: cohort studies and registry. Clin Exp Nephrol (2016) 0.78
A systems biology preview of the relationships between mineral and metabolic complications in chronic kidney disease. Semin Nephrol (2013) 0.78
Functional heterogeneity of osteocytes in FGF23 production: the possible involvement of DMP1 as a direct negative regulator. Bonekey Rep (2014) 0.78
Association of serum levels of FGF23 and α-Klotho with glomerular filtration rate and proteinuria among cardiac patients. BMC Nephrol (2014) 0.78
The relationship between circulating fibroblast growth factor 23 and bone metabolism factors in Korean hemodialysis patients. Clin Exp Nephrol (2010) 0.78
[FGF23 and Klotho: the new cornerstones of phosphate/calcium metabolism]. Arch Pediatr (2011) 0.76
Kbus/Idr, a mutant mouse strain with skeletal abnormalities and hypophosphatemia: identification as an allele of 'Hyp'. J Biomed Sci (2011) 0.76
Shedding quantitative fluorescence light on novel regulatory mechanisms in skeletal biomedicine and biodentistry. Jpn Dent Sci Rev (2016) 0.75
What can FGF23 do without Klotho? Bonekey Rep (2014) 0.75
Intact fibroblast growth factor-23 in plasma from Gambian children: response to the letter from Smith et al. Osteoporos Int (2013) 0.75
Model-Based Analysis of FGF23 Regulation in Chronic Kidney Disease. Gene Regul Syst Bio (2010) 0.75
Seven novel and six de novo PHEX gene mutations in patients with hypophosphatemic rickets. Int J Mol Med (2016) 0.75
Fibroblast Growth Factor 23 and Hypophosphatemia: A Case of Hypophosphatemia along the Rickets-Osteomalacia Spectrum. Cardiorenal Med (2016) 0.75
Plasma intact fibroblast growth factor 23 levels in women with bulimia nervosa: A cross-sectional pilot study. Biopsychosoc Med (2011) 0.75
Secondary hyperparathyroidism as a palpable intrathyroid parathyroid gland in a patient with hypophosphatemic osteomalacia. J Bone Miner Metab (2006) 0.75
Cholecalciferol decreases inflammation and improves vitamin D regulatory enzymes in lymphocytes in the uremic environment: A randomized controlled pilot trial. PLoS One (2017) 0.75
Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet (2006) 7.53
Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab (2006) 3.57
Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol (2006) 3.36
Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. JAMA (2005) 3.16
How fibroblast growth factor 23 works. J Am Soc Nephrol (2007) 2.92
Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem (2003) 2.91
Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study. Ann Intern Med (2013) 2.74
Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol (2007) 2.16
Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity. Sci Transl Med (2011) 2.14
Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol (2007) 2.12
Comparison of aneroid and oscillometric blood pressure measurements in children. J Clin Hypertens (Greenwich) (2013) 2.02
Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev (2012) 1.97
Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int (2005) 1.96
Identification of a novel extracellular cation-sensing G-protein-coupled receptor. J Biol Chem (2005) 1.86
High incidence of kidney stones in Icelandic children. Pediatr Nephrol (2005) 1.77
Autosomal dominant pseudohypoparathyroidism type Ib is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS. J Clin Invest (2003) 1.77
Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J (2011) 1.74
Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet (2009) 1.73
GPRC6A regulates prostate cancer progression. Prostate (2011) 1.68
GPRC6A null mice exhibit osteopenia, feminization and metabolic syndrome. PLoS One (2008) 1.63
Temporal trends in the incidence of kidney stone disease. Kidney Int (2012) 1.59
Assessment of 24,25(OH)2D levels does not support FGF23-mediated catabolism of vitamin D metabolites. Kidney Int (2012) 1.57
Association of variants at UMOD with chronic kidney disease and kidney stones-role of age and comorbid diseases. PLoS Genet (2010) 1.57
Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res (2012) 1.55
Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background. J Clin Invest (2003) 1.53
ASARM mineralization hypothesis: a bridge too far? J Bone Miner Res (2010) 1.51
Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol (2009) 1.45
Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial (2007) 1.42
Inhibition of MEPE cleavage by Phex. Biochem Biophys Res Commun (2002) 1.41
Do high levels of n-3 polyunsaturated fatty acids in cell membranes increase the risk of postoperative atrial fibrillation? Cardiology (2013) 1.39
GPRC6A mediates the non-genomic effects of steroids. J Biol Chem (2010) 1.38
Prevalence of chronic kidney disease based on estimated glomerular filtration rate and proteinuria in Icelandic adults. Nephrol Dial Transplant (2005) 1.33
GPRC6A mediates responses to osteocalcin in β-cells in vitro and pancreas in vivo. J Bone Miner Res (2011) 1.32
Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol (2005) 1.30
Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol (2009) 1.30
Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol (2008) 1.30
FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol (2008) 1.28
Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res (2012) 1.28
Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J Clin Invest (2014) 1.24
Calcium-sensing receptor activation of rho involves filamin and rho-guanine nucleotide exchange factor. Endocrinology (2002) 1.24
Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. Curr Opin Nephrol Hypertens (2007) 1.21
Selective Runx2-II deficiency leads to low-turnover osteopenia in adult mice. Dev Biol (2005) 1.20
A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One (2012) 1.20
Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype. J Biol Chem (2001) 1.20
Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. Am J Physiol Endocrinol Metab (2007) 1.19
Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype. Am J Physiol Endocrinol Metab (2010) 1.19
Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol (2007) 1.18
Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin. Bone (2006) 1.18
Conditional deletion of Pkd1 in osteocytes disrupts skeletal mechanosensing in mice. FASEB J (2011) 1.16
Does treatment with n-3 polyunsaturated fatty acids prevent atrial fibrillation after open heart surgery? Europace (2010) 1.15
Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease. Kidney Int (2013) 1.13
Calcium regulates FGF-23 expression in bone. Endocrinology (2013) 1.09
The role of RAGE in the pathogenesis of intestinal barrier dysfunction after hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol (2006) 1.08
Survival advantage in black versus white men with CKD: effect of estimated GFR and case mix. Am J Kidney Dis (2013) 1.07
Dose-dependent effects of Runx2 on bone development. J Bone Miner Res (2009) 1.06
Beta-arrestin- and G protein receptor kinase-mediated calcium-sensing receptor desensitization. Mol Endocrinol (2005) 1.05
Multiligand specificity and wide tissue expression of GPRC6A reveals new endocrine networks. Endocrinology (2012) 1.03
Polycystin-1 regulates skeletogenesis through stimulation of the osteoblast-specific transcription factor RUNX2-II. J Biol Chem (2008) 1.03
Disruption of Kif3a in osteoblasts results in defective bone formation and osteopenia. J Cell Sci (2012) 1.01
IRES-dependent translational control of Cbfa1/Runx2 expression. J Cell Biochem (2003) 0.99
Conditional disruption of Pkd1 in osteoblasts results in osteopenia due to direct impairment of bone formation. J Biol Chem (2009) 0.99
Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift? Nat Clin Pract Nephrol (2008) 0.98
Genistein stimulates the osteoblastic differentiation via NO/cGMP in bone marrow culture. J Cell Biochem (2005) 0.96
Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease--role of sclerostin? PLoS One (2013) 0.95
Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol (2012) 0.95
GPRC6A mediates the effects of L-arginine on insulin secretion in mouse pancreatic islets. Endocrinology (2012) 0.93
Inhibition of adipocyte differentiation by phytoestrogen genistein through a potential downregulation of extracellular signal-regulated kinases 1/2 activity. J Cell Biochem (2008) 0.93
Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. Am J Kidney Dis (2010) 0.92
Transcriptional regulation of CXC-ELR chemokines KC and MIP-2 in mouse pancreatic acini. Am J Physiol Gastrointest Liver Physiol (2010) 0.92
Anabolic effects of a G protein-coupled receptor kinase inhibitor expressed in osteoblasts. J Clin Invest (2002) 0.91
Plasma n-3 and n-6 fatty acids and the incidence of atrial fibrillation following coronary artery bypass graft surgery. Eur J Clin Invest (2011) 0.91
Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss. Am J Physiol Endocrinol Metab (2004) 0.91
Osteoblast calcium-sensing receptor has characteristics of ANF/7TM receptors. J Cell Biochem (2005) 0.89
Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD. J Clin Endocrinol Metab (2010) 0.89
Blood pressure in children and target-organ damage later in life. Pediatr Nephrol (2009) 0.88
Impaired osteoblast function in GPRC6A null mice. J Bone Miner Res (2010) 0.87
Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells. Bioconjug Chem (2012) 0.87
Prevalence of hypertension in 9- to 10-year-old Icelandic school children. J Clin Hypertens (Greenwich) (2011) 0.87
A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium. J Bone Miner Res (2004) 0.87
Birth weight and childhood blood pressure. Curr Hypertens Rep (2012) 0.87
Novel bone endocrine networks integrating mineral and energy metabolism. Curr Osteoporos Rep (2013) 0.86
Inducible expression of Runx2 results in multiorgan abnormalities in mice. J Cell Biochem (2011) 0.84
Kif3a deficiency reverses the skeletal abnormalities in Pkd1 deficient mice by restoring the balance between osteogenesis and adipogenesis. PLoS One (2010) 0.84
Fibroblast growth factor 23: uremic toxin or innocent bystander in chronic kidney disease? Nephrol News Issues (2009) 0.84
Prevalence and progression of CRF in Iceland: a population-based study. Am J Kidney Dis (2002) 0.83
Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. J Nutr Biochem (2003) 0.82
The role of fibroblast growth factor-23 in cardiorenal syndrome. Nephron Clin Pract (2013) 0.81
Cationic nanostructured polymers for siRNA delivery in murine calvarial pre-osteoblasts. J Biomed Nanotechnol (2014) 0.81
ADP-ribosylation factor 1 protein regulates trypsinogen activation via organellar trafficking of procathepsin B protein and autophagic maturation in acute pancreatitis. J Biol Chem (2012) 0.81